Last reviewed · How we verify

Calibvi (CAPLACIZUMAB)

Ablynx Nv · FDA-approved approved Monoclonal antibody Quality 65/100

Calibvi works by binding to von Willebrand factor, preventing it from interacting with platelets and forming blood clots.

Calibvi (Caplacizumab) is a small molecule drug developed by ABLYNX NV, targeting von Willebrand factor. It is used to treat thrombotic thrombocytopenic purpura (TTP), a rare blood disorder characterized by blood clots forming in small blood vessels. Calibvi was FDA-approved in 2019 and is currently patented. Key safety considerations include the risk of bleeding and thrombocytopenia. Calibvi works by binding to von Willebrand factor, preventing it from interacting with platelets and forming blood clots.

At a glance

Generic nameCAPLACIZUMAB
SponsorAblynx Nv
Targetvon Willebrand factor
ModalityMonoclonal antibody
Therapeutic areaMetabolic
PhaseFDA-approved
First approval2019

Mechanism of action

Imagine your blood vessels are like roads, and platelets are like cars. Von Willebrand factor is like a traffic light that helps platelets stick together and form clots. Calibvi is like a traffic light blocker that prevents the von Willebrand factor from working, keeping the roads clear and preventing clots from forming.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results